Navigation Links
Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
Date:10/11/2011

ANAHEIM, Calif., Oct. 11, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release third quarter 2011 financial results on Tuesday, October 25, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and slide presentation via webcast on Tuesday, October 25, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the third quarter, as well as current corporate developments.  

Conference call details:Date:Tuesday, October 25, 2Time:4:30 p.m. ETDial-in (U.S.):877-941-1465Dial-in (International):480-629-9643Web cast:www.questcor.comTo access an audio replay of the call:

Replay (U.S.):800-406-7325Replay (International):303-590-303Replay Passcode:4480054About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of infantile spasms in children under two years of age and the treatment of nephrotic syndrome. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
2. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
3. Questcor Provides Updated New Paid Prescription Trends
4. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
5. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
6. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
7. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
8. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
9. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
10. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
11. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):